CAJ | 학술논문

目的观察舒利迭联合孟鲁司特钠治疗重度慢性阻塞性肺疾病急性加重（AECOPD）的临床疗效。方法113例重度AECOPD 患者，随机分为舒利迭联合孟鲁司特钠治疗组57例，单纯舒利迭治疗组56例，治疗14d后，评价所有患者的运动耐力、血气分析与肺功能指标第一秒用力呼气量（F E V1）、第一秒用力呼气量占用力肺活量百分比（FEV1/FVC）。结果对照组与治疗组上述指标均较治疗前改善（P＜0.05与P＜0.01），但治疗组较对照组改善更为明显（P＜0.05），且药物治疗安全性好。结论孟鲁司特钠联合舒利迭治疗中重度AECOPD，疗效显著，能降低运动耐力评分、改善血气分析、促进患者肺功能的恢复。
목적관찰서리질연합맹로사특납치료중도만성조새성폐질병급성가중（AECOPD）적림상료효。방법113례중도AECOPD 환자，수궤분위서리질연합맹로사특납치료조57례，단순서리질치료조56례，치료14d후，평개소유환자적운동내력、혈기분석여폐공능지표제일초용력호기량（F E V1）、제일초용력호기량점용력폐활량백분비（FEV1/FVC）。결과대조조여치료조상술지표균교치료전개선（P＜0.05여P＜0.01），단치료조교대조조개선경위명현（P＜0.05），차약물치료안전성호。결론맹로사특납연합서리질치료중중도AECOPD，료효현저，능강저운동내력평분、개선혈기분석、촉진환자폐공능적회복。
Objective To investigate the clinical efficacy of montelukast joint Seretide treatment of severe AECOPD patients. Methods A total of 61 severe patients with AECOPD were randomly divided into two groups:montelukast in combination seretide with group(n=57),control group(n=56). Endurance ratings,blood gas analysis and parameters of pulmonary function(FEV1,FEV1/FVC)of al patients were assessed after 10-14 days' treatment. Results Compared with prior treatment,al indicators above of the two group improved a lot(P<0.05,P<0.01),but treatment group was even more apparent than control group(P<0.05)and with a sustained safety. Conclusions Combined montelukast and seretide has a significant effect on the treatment of severe patients with AECOPD by decreasing endurance ratings,improving blood gas analysis and promoting the recovery of pulmonary function.